Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has demonstrated, with highly statistically significant results, the ability of it's Homologous Recombination Deficiency Assay to detect loss of DNA repair in ovarian tumors.